Literature DB >> 1804642

Potentiation of vascular smooth muscle cell activity by cyclosporin A.

R Locher1, R Huss, W Vetter.   

Abstract

Pretreatment of rat vascular smooth muscle cells with cyclosporin A caused concentration- and time-dependent enhancement of both angiotensin II- and platelet-derived growth factor-stimulated cellular functions, which may be related to a rise in vascular tone. In particular, cyclosporin A increased cytosolic free calcium, and augmented the agonist-induced formation of inositol polyphosphate. In addition, it markedly increased the sensitivity of the cells to platelet-derived growth factor-mediated stimulation of thymidine incorporation. The potentiation of vascular smooth muscle cell activity by cyclosporin A may be a novel mechanism by which it exerts an adverse vasoconstrictor effect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804642     DOI: 10.1007/BF00314955

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

Review 1.  Intracellular calcium and smooth muscle contraction.

Authors:  L E Sommerville; D J Hartshorne
Journal:  Cell Calcium       Date:  1986-12       Impact factor: 6.817

Review 2.  Cyclosporin A: a selective anti-T cell agent.

Authors:  B D Kahan
Journal:  Clin Haematol       Date:  1982-10

3.  Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone system.

Authors:  M Bellet; C Cabrol; P Sassano; P Léger; P Corvol; J Ménard
Journal:  Am J Cardiol       Date:  1985-12-01       Impact factor: 2.778

4.  Preparation of biologically active platelet-derived growth factor isoforms AA and AB. Preferential formation of AB heterodimers.

Authors:  J Hoppe; H A Weich; W Eichner; D Tatje
Journal:  Eur J Biochem       Date:  1990-01-12

5.  Experimental cyclosporin A nephrotoxicity.

Authors:  P H Whiting; A W Thomson; J T Blair; J G Simpson
Journal:  Br J Exp Pathol       Date:  1982-02

6.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

7.  Identification of cyclosporin binding sites in rat liver plasma membranes, isolated hepatocytes, and hepatoma cells by photoaffinity labeling using [3H]cyclosporin-diaziridine.

Authors:  K Ziegler; M Frimmer
Journal:  Biochim Biophys Acta       Date:  1986-02-13

8.  Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury.

Authors:  L Jonasson; J Holm; G K Hansson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

9.  Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration.

Authors:  B Legg; S K Gupta; M Rowland; R W Johnson; L R Solomon
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers.

Authors:  R Ross
Journal:  J Cell Biol       Date:  1971-07       Impact factor: 10.539

View more
  4 in total

1.  Vascular remodelling in intramyocardial resistance vessels in hypertensive human cardiac transplant recipients.

Authors:  J T Jenkins; J J Boyle; I C McKay; D Richens; A R McPhaden; G B Lindop
Journal:  Heart       Date:  1997-04       Impact factor: 5.994

2.  Effects of cyclosporin and FK-506 on glomerular mesangial cells. Evidence for direct inhibition of thromboxane synthase by low cyclosporin concentrations.

Authors:  H H Radeke; S Kuster; V Kaever; K Resch
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Cellular signaling by cyclosporine A in contractile cells: interactions with atrial natriuretic peptide.

Authors:  H Meyer-Lehnert; D Bokemeyer; U Friedrichs; S Drechsler; H J Kramer
Journal:  Clin Investig       Date:  1993-02

4.  Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity.

Authors:  A Lo Russo; A C Passaquin; P André; M Skutella; U T Rüegg
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.